CoChat

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients

Open access
Vincenzi, Bruno, Cremolini, Chiara, Sartore-Bianchi, Andrea, Russo, Antonio, Mannavola, Francesco, Perrone, Giuseppe, Pantano, Francesco, Loupakis, Fotios, Rossini, Daniele, Ongaro, Elena, Bonazzina, Erica, Dell’Aquila, Emanuela, Imperatori, Marco, Zoccoli, Alice, Bronte, Giuseppe, De Maglio, Giovanna, Fontanini, Gabriella, Natoli, Clara, Falcone, Alfredo, Santini, Daniele, Onetti-Muda, Andrea, Siena, Salvatore, Tonini, Giuseppe, Aprile, Giuseppe · 2015 · Oncotarget
Cited by 36

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

// Bruno Vincenzi 1 , Chiara Cremolini 2 , Andrea Sartore-Bianchi 3 , Antonio Russo 4 , Francesco Mannavola 5 , Giuseppe Perrone 6 , Francesco Pantano 1 , Fotios Loupakis 2 , Daniele Rossini 2 , Elena Ongaro 7 , Erica Bonazzina 3 , Emanuela Dell’Aquila 1 , Marco Imperatori 1 , Alice Zoccoli 1 , Giuseppe Bronte 4 , Giovanna De Maglio 7 , Gabriella Fontanini 8 , Clara Natoli 9 , Alfredo Falcone 2 , Daniele Santini 1 , Andrea Onetti-Muda 6 , Salvatore Siena 3 , Giuseppe Tonini 1 and Giuseppe Aprile 7 1 Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy 2 Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy 3 Niguarda Cancer Center, Ospedale Niguarda Ca’ Granda, Milano, Italy 4 Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy 5 Università Cattolica del Sacro Cuore, Rome, Italy 6 Department of Anatomical Pathology, Campus Bio-Medico University of Rome, Rome, Italy 7 Department of Medical Oncology, Azienda Ospedaliero-Universitaria, Udine, Italy 8 Dipartimento di Patologia Chirurgica, Medica, Molecolare e dell’Area Critica, Università di Pisa, Pisa, Italy 9 Department of Medical, Oral and Biotechnological Sciences, University “G. D’Annunzio”, Chieti, Italy Correspondence to: Antonio Russo, email: // Bruno Vincenzi, email: // Keywords : K-Ras, mutation rate, colorectal cancer, bevacizumab, prognosis Received : July 20, 2015 Accepted : August 09, 2015 Published : August 19, 2015 Abstract Introduction: Activating mutations of K-Ras gene have a well-established role as predictors of resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer (mCRC) patients. Their prognostic value is controversial, and no data regarding the prognostic value of mutation rate, defined as the percentage of mutated alleles/tumor sample, are available. We aimed to evaluate the prognostic value of K-Rasmutation rate in a homogenous cohort of mCRC patients receiving first-line doublet plus bevacizumab. Patients and Methods: This retrospective study enrolled 397 K-Ras mutant mCRC patients from 6 Italian centers, and 263 patients were fully evaluable for our analysis. K-Ras mutation rate was assessed by pyrosequencing. Patients with less than 60% of cancer cells in tumor tissue were excluded. No patients received anti-EGFR containing anticancer therapy, at any time. Median mutation rate was 40% and was adopted as cut-off. The primary and secondary endpoints were PFS and OS respectively. Results: At univariate analysis, K-Ras mutation rate higher than 40% was significantly associated with lower PFS (7.3 vs 9.1 months; P < 0.0001) and OS (21 vs 31 months; P = 0.004). A multivariate model adjusted for age at diagnosis, site of origin of tumor tissue (primary vs metastases), referral center, number of metastatic sites, and first-line chemotherapy backbone, showed that K-Ras mutation rate remained a significant predictor of PFS and OS in the whole population. Discussion: Our data demonstrate an association between K-Ras mutation rate and prognosis in mCRC patients treated with bevacizumab-containing first-line therapy. These data deserve to be verified in an independent validation set.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.5231

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 36

Metadata

Authors
Vincenzi, B., Cremolini, C., Sartore-Bianchi, A., Russo, A., Mannavola, F., Perrone, G., Pantano, F., Loupakis, F., Rossini, D., Ongaro, E., Bonazzina, E., Dell’Aquila, E., Imperatori, M., Zoccoli, A., Bronte, G., De Maglio, G., Fontanini, G., Natoli, C., Falcone, A., Santini, D., Onetti-Muda, A., Siena, S., Tonini, G., & Aprile, G.
Venue
Oncotarget
Published
2015-08-19
Volume
6
Issue
31
Pages
31604-31612
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1857311025
Cited by
36
References
9
FWCI
2.34
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. https://app.cochat.ai/papers/10.18632/oncotarget.5231
The paper
Vincenzi, B., Cremolini, C., Sartore-Bianchi, A., Russo, A., Mannavola, F., Perrone, G., Pantano, F., Loupakis, F., Rossini, D., Ongaro, E., Bonazzina, E., Dell’Aquila, E., Imperatori, M., Zoccoli, A., Bronte, G., De Maglio, G., Fontanini, G., Natoli, C., Falcone, A., . . . Aprile, G. (2015). Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Oncotarget. https://doi.org/10.18632/oncotarget.5231

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.